Less Ads, More Data, More Tools Register for FREE

Pin to quick picksM P Evans Regulatory News (MPE)

Share Price Information for M P Evans (MPE)

Share Price is delayed by 15 minutes
Get Live Data
1,482.00    -20.00 (-1.33%)
Bid:
1,468.00
Ask:
1,478.00
Spread: 10.00 (0.681%)
Market Cap: £772.28m
MPE Live PriceLast checked at - London Stock Exchange

Intraday M P Evans Share Chart

Acquisition

6 Mar 2023 07:00

RNS Number : 8974R
M. P. Evans Group PLC
06 March 2023
 

M.P. EVANS GROUP PLC

("The Group" or "M.P.Evans")

 

ACQUISITION OF PLANTED LAND IN INDONESIA

 

The board of M.P.Evans, the producer of sustainable palm oil, is pleased to announce, in line with its growth strategy, the acquisition, for cash, of additional planted land, adjacent to the Group's Simpang Kiri estate, in Indonesia.

 

The Group has been successful in acquiring 100% of the shares in two Indonesian companies, PT Teunggulon Raya and PT Dharma Agung, which between them own 2,100 hectares planted with oil palm. All the land being acquired is fully titled, with long leaseholds already established with the Indonesian government, in a similar way to the Group's existing properties. The planted land is close to the Group's Simpang Kiri estate in Aceh Province, Northern Sumatra. Total costs associated with the acquisition, including the assumption of liabilities within the companies acquired, are estimated to be US$14.3 million, giving rise to a purchase cost of US$6,800 per hectare. The Group does expect to replant some of the acquired areas in the near term, as part of its plans to bring them up to Group standards.

 

Following the acquisition, the Group will have an expanded planted area of 4,800 hectares at or around the Simpang Kiri estate, and the potential to build its own palm-oil mill there. If one is developed, the Group would reach a position of processing 100% of its own crop, as well as further increasing its sustainable palm-oil production.

 

Commenting on the acquisition, Peter Hadsley-Chaplin, executive chairman, said:

 

"This is an excellent acquisition, fully in keeping with our stated strategy and supported by the strength of the Group's balance sheet. Thanks to a combination of the good price at which it has been secured, and the added scale it gives the Group around Simpang Kiri, these additional hectares are further fuel for the M.P.Evans growth engine."

 

6 March 2023

 

Enquiries:

M.P. Evans Group PLC

+44 (0)1892 516333

Peter Hadsley-Chaplin

Executive chairman

Matthew Coulson

Chief executive

Luke Shaw

Chief financial officer

Peel Hunt LLP (Nomad and joint broker)

+44 (0)20 7418 8900

Dan Webster, Andrew Clark, Lalit Bose

finnCap (Joint broker)

+44 (0)20 7220 0500

Tim Redfern, Harriet Ward

Hudson Sandler (Financial PR)

+44 (0)20 7796 4133

Charlie Jack, Francis Kerrigan, Amelia Craddock

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUPUAUWUPWGAW
Date   Source Headline
19th Mar 20247:00 amRNSFinal Results
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSNotice of Results
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20249:50 amRNSTotal Voting Rights
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSPublication of ESG report
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 202410:50 amRNSTotal Voting Rights
1st Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20247:00 amRNSTransaction in Own Shares
26th Jan 20247:00 amRNSTransaction in Own Shares
25th Jan 20247:00 amRNSTransaction in Own Shares
24th Jan 20247:00 amRNSTransaction in Own Shares
23rd Jan 20247:00 amRNSTransaction in Own Shares
19th Jan 20247:30 amRNSTransaction in Own Shares
19th Jan 20247:00 amRNSCrop and Production
12th Jan 20247:10 amRNSChange of Adviser
5th Jan 202411:06 amRNSDirector/PDMR Shareholding
2nd Jan 20243:35 pmRNSTotal Voting Rights
2nd Jan 20243:16 pmRNSBlock listing Interim Review
15th Dec 20237:00 amRNSTransaction in Own Shares
14th Dec 20237:00 amRNSTransaction in Own Shares
13th Dec 20239:02 amRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSTransaction in Own Shares
11th Dec 20237:00 amRNSTransaction in Own Shares
7th Dec 20237:00 amRNSTransaction in Own Shares
4th Dec 20235:07 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSTransaction in Own Shares
29th Nov 20237:00 amRNSTransaction in Own Shares
28th Nov 20237:00 amRNSTransaction in Own Shares
27th Nov 20237:00 amRNSTransaction in Own Shares
27th Nov 20237:00 amRNSAcquisition
24th Nov 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.